Summit counters PD-1/VEGF skeptics; Celldex drug fails skin disease study

Data ReadoutnegativeNegative

AI Analysis

Summary

Celldex Therapeutics announced that its drug candidate failed a skin disease study, while Summit Therapeutics counters skepticism regarding PD-1/VEGF combination approaches.

Clinical Trial Data

Primary Endpoint

Not Met

Outcome Details

Celldex drug failed skin disease study

Importance:5/10

Sentiment:

-0.70

clinical_trialdata_readoutoncologyimmunotherapyfailure

Related Companies

$SMMT $CLDX

Read the original article

Published by yahoo_finance on July 22, 2026 9:33 AM

Read Original